Strata Critical Medical (SRTA) Stock Overview
Provides time-critical logistics and medical services to the healthcare industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SRTA Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Strata Critical Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.13 |
| 52 Week High | US$6.02 |
| 52 Week Low | US$3.31 |
| Beta | 2.15 |
| 1 Month Change | 22.60% |
| 3 Month Change | 36.22% |
| 1 Year Change | 81.36% |
| 3 Year Change | 100.98% |
| 5 Year Change | -36.93% |
| Change since IPO | -37.13% |
Recent News & Updates
Analysis Article • May 08
Strata Critical Medical, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...
Narrative Update • May 08
SRTA: Higher 2026 Guidance And Mixed Risk Signals Will Support Future Upside
Analysts have nudged their average price target for Strata Critical Medical higher by $0.25, reflecting a slightly stronger profit outlook and updated P/E assumptions. At the same time, they have tempered revenue growth expectations and applied a modestly higher discount rate.Recent updates
Analysis Article • May 08
Strata Critical Medical, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...Narrative Update • May 08
SRTA: Higher 2026 Guidance And Mixed Risk Signals Will Support Future Upside
Analysts have nudged their average price target for Strata Critical Medical higher by $0.25, reflecting a slightly stronger profit outlook and updated P/E assumptions. At the same time, they have tempered revenue growth expectations and applied a modestly higher discount rate.
Narrative Update • Apr 20
SRTA: Bullish Execution On Raised 2026 Revenue Outlook May Unlock Future Upside
The Analyst Price Target for Strata Critical Medical has been revised from $9.63 to $8.81, with analysts pointing to updated assumptions on revenue growth, profit margins, and a higher forward P/E multiple, despite generally bullish recent coverage. Analyst Commentary Recent research coverage on Strata Critical Medical has been largely constructive, with analysts updating their models to reflect revised assumptions on revenue, margins, and valuation multiples.Narrative Update • Apr 06
SRTA: Raised Revenue Outlook And Richer Future P/E Will Support Upside
Analysts have raised their price target on Strata Critical Medical to $8.00 per share, citing updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, supported by recent bullish initiation reports from multiple firms. Analyst Commentary Recent bullish initiation reports on Strata Critical Medical highlight constructive views on the company’s long term prospects, but not all commentary is aligned with that optimism.Narrative Update • Mar 23
SRTA: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their price target on Strata Critical Medical to $8.00. This reflects updated assumptions for significantly higher revenue growth, lower profit margins, and a substantially higher future P/E multiple.Narrative Update • Mar 09
SRTA: Higher Revenue Outlook And Impairment Charge Will Support Future Upside
Analysts have adjusted their price target on Strata Critical Medical to $9.63, reflecting updated assumptions that combine a different discount rate and future P/E with materially higher modeled revenue growth and slightly lower profit margins. What's in the News Strata Critical Medical raised its 2026 revenue guidance to a range of $260 million to $275 million, compared with the prior range of $255 million to $270 million (Key Developments).Narrative Update • Feb 22
SRTA: Higher Margin Outlook Will Support Future Earnings Power
Analysts have adjusted their price target on Strata Critical Medical to $8.00, reflecting updated assumptions for slightly higher revenue, improved profit margins, a modestly higher discount rate, and a lower future P/E multiple. Valuation Changes Fair Value: $8.00 stays unchanged, with the revised assumptions still pointing to the same central estimate.
Narrative Update • Feb 07
SRTA: Higher Margins And Updated Guidance Will Support Stronger Future Returns
Analysts have modestly reset their price target for Strata Critical Medical to $11.25, citing updated assumptions around slightly higher revenue growth, tighter profit margins at 18.60% and a lower future P/E of about 25.74x as key drivers of the revised view. What's in the News Strata Critical Medical issued earnings guidance for 2026, expecting revenue between $255 million and $270 million.Narrative Update • Jan 24
SRTA: Higher Margin Outlook And Revenue Guidance Will Support Earnings Power
Analysts have adjusted their price target on Strata Critical Medical to $8.00. The updated view reflects slightly different assumptions around revenue growth, profit margin and future P/E that they see as better aligning with their current outlook for the business.Narrative Update • Jan 09
SRTA: Higher Margin Outlook Will Drive Stronger Earnings Power Ahead
Analysts have raised their fair value estimate for Strata Critical Medical from $5.00 to $8.00, citing updated assumptions that include a lower discount rate, a revised outlook for revenue growth, higher expected profit margins, and a reduced future P/E multiple. What's in the News Strata Critical Medical issued earnings guidance for 2026, with expected revenue in a range of $255 million to $270 million.Analysis Article • Jan 06
Strata Critical Medical, Inc.'s (NASDAQ:SRTA) 30% Price Boost Is Out Of Tune With Revenues
Strata Critical Medical, Inc. ( NASDAQ:SRTA ) shares have had a really impressive month, gaining 30% after a shaky...Narrative Update • Dec 17
SRTA: Lower Risk Profile And Rising Margins Will Drive Stronger Future Returns
Analysts have raised their price target for Strata Critical Medical from 6.50 dollars to 11.25 dollars, citing a lower perceived risk profile and materially stronger long term profitability expectations, despite moderating revenue growth assumptions and a slightly lower future P E multiple. What's in the News Strata Critical Medical issued 2026 revenue guidance, forecasting between 255 million dollars and 270 million dollars.Narrative Update • Dec 03
SRTA: Keystone Acquisition Will Drive Expanded Cash Deployment And Future Earnings Upside
Analysts have nudged their price target on Strata Critical Medical higher to $9.63 from $9.25, citing the strategically accretive Keystone Perfusion Services acquisition and the company’s more constructive growth outlook as key drivers. Analyst Commentary Bullish analysts view the Keystone Perfusion Services acquisition as a strategically important use of Strata Critical Medical's sizable cash balance.Narrative Update • Nov 19
SRTA: Keystone Acquisition Will Drive Material Revenue Expansion And Lower Risk
Analysts have raised their price target for Strata Critical Medical to $7.25, up from $6.50. They cite strong support for the company's recent acquisition of Keystone Perfusion Services as a strategic use of its significant cash reserves.Narrative Update • Nov 03
SRTA: Cash Deployment Through Acquisition Will Drive Expansion In Healthcare Reach
Analysts have raised their price target for Strata Critical Medical to $9.25, up from $7.83. They cited stronger strategic deployment of cash resources with the acquisition of Keystone Perfusion Services and improved expectations for future performance.Narrative Update • Sep 23
Critical Organ Transport And Joby Aviation Will Expand Healthcare Reach
Strata Critical Medical’s consensus price target has risen from $5.83 to $7.83, as analysts express increased confidence in management’s ability to deploy capital efficiently and drive shareholder value following the accretive acquisition of Keystone Perfusion Services. Analyst Commentary Bullish analysts highlight the successful deployment of Strata's large $235M pro forma cash position through the acquisition of Keystone Perfusion Services for $124M.Narrative Update • Aug 06
Critical Organ Transport And Joby Aviation Will Expand Healthcare Reach
The consensus analyst price target for Blade Air Mobility has increased, primarily driven by higher revenue growth forecasts and a rising future P/E, bringing the fair value estimate up from $7.20 to $7.75. What's in the News Joby Aviation is exploring an acquisition of Blade Air Mobility to access a ready customer base for electric air taxis; no final decision has been made.Analysis Article • May 15
Earnings Release: Here's Why Analysts Cut Their Blade Air Mobility, Inc. (NASDAQ:BLDE) Price Target To US$7.20
Blade Air Mobility, Inc. ( NASDAQ:BLDE ) investors will be delighted, with the company turning in some strong numbers...Analysis Article • May 13
Blade Air Mobility, Inc. (NASDAQ:BLDE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Those holding Blade Air Mobility, Inc. ( NASDAQ:BLDE ) shares would be relieved that the share price has rebounded 29...
New Narrative • Mar 31
eVTOL And Urban Air Mobility Will Open New Routes
Transition to electric vertical aircraft (eVTOL) promises long-term growth by enabling new routes and attracting a wider customer base.Seeking Alpha • Feb 26
Blade Air Mobility: Organ Transport Growth Now, eVTOL Growth Later
Summary Blade currently focuses on organ transport and passenger transport. The company is expanding in the organ logistics market. New perfusion technologies and competition provide a risk to the business. Air taxi services using eVTOLs provide a margin expansion opportunity. The stock is a speculative buy at this point. Read the full article on Seeking AlphaAnalysis Article • Nov 30
Revenues Not Telling The Story For Blade Air Mobility, Inc. (NASDAQ:BLDE) After Shares Rise 27%
Despite an already strong run, Blade Air Mobility, Inc. ( NASDAQ:BLDE ) shares have been powering on, with a gain of...Seeking Alpha • Nov 18
Blade: Transition To Profitability Should Provide Support Going Forward
Summary Blade's growth was weak in Q3, largely due to the company abandoning activities with marginal economics. Policy reforms and new technologies are driving growth in transplant volumes and transportation distances but competition is likely to increase in coming quarters. Provided Blade's margins continue to improve, the stock should move higher at some point. This will likely require an improvement in growth though. eVTOLs should provide Blade's passenger segment with a significant boost but this remains several years away. Read the full article on Seeking AlphaAnalysis Article • Nov 15
Analysts Have Made A Financial Statement On Blade Air Mobility, Inc.'s (NASDAQ:BLDE) Third-Quarter Report
Last week, you might have seen that Blade Air Mobility, Inc. ( NASDAQ:BLDE ) released its third-quarter result to the...Analysis Article • Sep 16
Blade Air Mobility, Inc.'s (NASDAQ:BLDE) Business Is Trailing The Industry But Its Shares Aren't
When you see that almost half of the companies in the Airlines industry in the United States have price-to-sales ratios...Seeking Alpha • Aug 15
Blade: Margins Remain An Issue
Summary Blade Air Mobility, Inc.'s business continues to expand, but revenue growth is being dampened by the company's decision to discontinue unprofitable activities. Competition from TransMedics poses a threat, and this issue is likely to come to a head in coming quarters. While Blade has managed to reduce its losses, stock-based compensation is causing fairly significant dilution. Blade's low valuation could be an opportunity, but the company probably needs to stabilize its growth and address dilution before the stock moves higher. Read the full article on Seeking AlphaAnalysis Article • Jun 19
Here's Why We're Not At All Concerned With Blade Air Mobility's (NASDAQ:BLDE) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • May 16
Blade Air Mobility: No Signs Of Competition Yet
Summary Rising organ transportation competition poses a threat to Blade's Medical segment, but Q1 revenue suggests there hasn't been a material impact so far. TransMedics' strong logistics growth and aggressive expansion plan put Blade and TransMedics on a collision course in coming years. Blade's valuation is low though, and if the Medical segment continues to grow or eVTOLs expand the UAM market, the stock could perform well. Read the full article on Seeking AlphaAnalysis Article • May 10
Analysts Are Updating Their Blade Air Mobility, Inc. (NASDAQ:BLDE) Estimates After Its First-Quarter Results
Blade Air Mobility, Inc. ( NASDAQ:BLDE ) defied analyst predictions to release its first-quarter results, which were...Analysis Article • Mar 20
Blade Air Mobility, Inc.'s (NASDAQ:BLDE) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Blade Air Mobility, Inc. ( NASDAQ:BLDE ) share price has fared very poorly over the last month, falling by a...Analysis Article • Mar 15
Blade Air Mobility, Inc. (NASDAQ:BLDE) Annual Results: Here's What Analysts Are Forecasting For This Year
Shareholders in Blade Air Mobility, Inc. ( NASDAQ:BLDE ) had a terrible week, as shares crashed 32% to US$2.62 in the...Shareholder Returns
| SRTA | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 17.4% | -0.4% | 1.0% |
| 1Y | 81.4% | 16.3% | 28.7% |
Return vs Industry: SRTA exceeded the US Healthcare industry which returned 14.6% over the past year.
Return vs Market: SRTA exceeded the US Market which returned 27.1% over the past year.
Price Volatility
| SRTA volatility | |
|---|---|
| SRTA Average Weekly Movement | 7.5% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SRTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SRTA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 327 | Melissa Tomkiel | www.stratacritical.com |
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services.
Strata Critical Medical, Inc. Fundamentals Summary
| SRTA fundamental statistics | |
|---|---|
| Market cap | US$501.85m |
| Earnings (TTM) | -US$16.05m |
| Revenue (TTM) | US$228.58m |
2.3x
P/S Ratio-33.0x
P/E RatioIs SRTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRTA income statement (TTM) | |
|---|---|
| Revenue | US$228.58m |
| Cost of Revenue | US$180.39m |
| Gross Profit | US$48.19m |
| Other Expenses | US$64.24m |
| Earnings | -US$16.05m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 21.08% |
| Net Profit Margin | -7.02% |
| Debt/Equity Ratio | 0% |
How did SRTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 22:38 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Strata Critical Medical, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Itay Michaeli | Citigroup Inc |
| William Bonello | Craig-Hallum Capital Group LLC |